Therapy with intravenous immunoglobulins: complications and side-effects
- PMID: 14530624
- DOI: 10.1159/000073059
Therapy with intravenous immunoglobulins: complications and side-effects
Abstract
Therapy with intravenous immunoglobulins (IVIG) is thought to be a safe treatment for a number of immune-mediated neurological diseases. Published data about prevalence of adverse effects range from 11 to 81%. The purpose of our study was to present a representative view on adverse effects by analysis of a large cohort of patients treated by IVIG. In a prospective study, we analysed 117 patients (age 17-79 years) who were treated with IVIG for various neurological diseases including chronic inflammatory demyelinating polyneuropathy, diabetic amyotrophy, inclusion body myositis, multiple sclerosis, Guillain-Barré syndrome, Miller-Fisher syndrome, multifocal motor neuropathy, myasthenia gravis and polymyositis. IVIG therapy was applied at a dose of 0.4 g/kg body weight/day in a total of 408 therapy courses. 42.7% showed adverse events. The majority of patients presented with minor adverse effects, mostly asymptomatic laboratory changes. Rash or mild headache occurred in 8 patients, especially when IVIG was given with infusion flow higher than 10 g/h. Two patients showed a severe complication with deep vein thrombosis. In summary, beside its effectiveness in immune mediated neurological diseases, therapy with IVIG seems to be a safe therapy. Most patients show no or minor adverse effects. Patients with pre-existent disorders like heart or renal insufficiency or immobilised patients, however, may be at higher risk for complications.
Copyright 2003 S. Karger AG, Basel
Similar articles
-
Adverse effects of treatment with intravenous immunoglobulins for neurological diseases.J Neurol. 2006 Sep;253 Suppl 5:V75-9. doi: 10.1007/s00415-006-5013-z. J Neurol. 2006. PMID: 16998759 Review.
-
Intravenous immunoglobulin in autoimmune neuromuscular diseases.JAMA. 2004 May 19;291(19):2367-75. doi: 10.1001/jama.291.19.2367. JAMA. 2004. PMID: 15150209 Review.
-
Intravenous immune globulin therapy for neurologic diseases.Ann Intern Med. 1997 May 1;126(9):721-30. doi: 10.7326/0003-4819-126-9-199705010-00008. Ann Intern Med. 1997. PMID: 9139559 Review.
-
Side effects of intravenous immunoglobulins in neurological autoimmune disorders--a prospective study.J Neurol. 2003 Jul;250(7):818-21. doi: 10.1007/s00415-003-1085-1. J Neurol. 2003. PMID: 12883923
-
Safety of intravenous immunoglobulin in the elderly treated for a dysimmune neuromuscular disease.Muscle Nerve. 2016 May;53(5):683-9. doi: 10.1002/mus.24942. Epub 2016 Jan 19. Muscle Nerve. 2016. PMID: 26467654
Cited by
-
Case-control study of thromboembolic events associated with IV immunoglobulin.J Neurol. 2009 Mar;256(3):339-42. doi: 10.1007/s00415-009-0969-0. Epub 2009 Mar 1. J Neurol. 2009. PMID: 19253011
-
Effect of early treatment with polyvalent immunoglobulin on acute respiratory distress syndrome associated with SARS-CoV-2 infections (ICAR trial): study protocol for a randomized controlled trial.Trials. 2021 Feb 28;22(1):170. doi: 10.1186/s13063-021-05118-7. Trials. 2021. PMID: 33648563 Free PMC article.
-
Intravenous Immune Globulin Uses in the Fetus and Neonate: A Review.Antibodies (Basel). 2020 Nov 4;9(4):60. doi: 10.3390/antib9040060. Antibodies (Basel). 2020. PMID: 33158209 Free PMC article. Review.
-
Guillain-Barré syndrome AMSAN variant in a 90-year-old woman after COVID-19: a case report.BMC Geriatr. 2023 Mar 1;23(1):114. doi: 10.1186/s12877-023-03833-1. BMC Geriatr. 2023. PMID: 36859256 Free PMC article.
-
[Use of i.v. immunoglobulins in neurology. Evidence-based consensus].Nervenarzt. 2004 Aug;75(8):801-15. doi: 10.1007/s00115-004-1733-4. Nervenarzt. 2004. PMID: 15224177 Review. German.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
